Industry Briefs April 2022 | PM360

Collaboration Aims to Revolutionize Vaccine Development The physIQ Sensor System is a medical-grade biosensor that will be used as part of a new study examining vaccination responses. physIQ, a pioneer in digital medicine, and CellCarta, a global contract research organization (CRO) specializing in precision medicine services, announced a partnership on a study to monitor individual … Read more

What now? Alzheimer’s drugmakers ponder the path to approval

Listen to the article 7 min This audio is auto-generated. Please let us know if you have feedback. Last week, Medicare rendered a fateful decision that’s become the latest flashpoint in Biogen’s ongoing saga with Aduhelm. As part of a new finalized policy, the Centers for Medicare and Medicaid Services (CMS) will limit coverage for … Read more

Healthcare Watch April 2022 | PM360

Doctor Docs: Physicians are Fed Up with COVID-19 Misinformation According to a Sermo survey, 81% of physicians say social media misinformation has caused an existential crisis in their profession. Around the world, 55% of physicians are saying that COVID vaccine misinformation is-19 becoming an issue when meeting with patients, according to a Sermo survey of … Read more

With Lilly on board, Entos’ medical chief champions genetic platform with ‘unlimited’ potential

Listen to the article 6 min This audio is auto-generated. Please let us know if you have feedback. Entos Pharmaceuticals is on the verge of “leveling up,” and Steve Chen is excited to help them get there. “I think the company right now is actually going through what I would call a major inflection point,” … Read more

Two Key Questions About Payer Strategies in 2022

PM360 We asked experts in dealing with payers to tell us the optimal strategies for negotiating pricing and formularies and the continued push toward value-based models. Specifically, we wanted to know: What are the keys to successful payer-pharma negotiations in 2022? What data do payers most value from pharma? How are the other needs or … Read more

How pharma can up its social media game

Listen to the article 8 min This audio is auto-generated. Please let us know if you have feedback. The life sciences sector long shied away from advertising on social media platforms, largely fearing the FDA’s stringent regulations. Now, more biopharma companies are jumping into the online direct-to-consumer marketing game. After all, with over 50% of … Read more

Establishing a Successful Pharma-Payer Relationship in 2022

If a life sciences company wants to start their relationship with a payer off on the right foot, then they better be prepared to deliver them some PIE. No, we don’t mean a delicious pastry, but pre-approval information exchange (PIE). Today’s payers want more information about a product sooner than ever. According to an Xcenda … Read more

A pharma mystery: Cancer-causing impurities drive joint search for answers

Listen to the article 9 min This audio is auto-generated. Please let us know if you have feedback. In the complicated world of pharmaceutical development and manufacturing, it’s little wonder there are still a few mysteries. Potentially carcinogenic compounds called nitrosamines — and how they come to be in certain drugs — are one of … Read more

For Global Blood Therapeutics, the connection to sickle cell disease runs deep

Listen to the article 7 min This audio is auto-generated. Please let us know if you have feedback. Many disadvantaged young Black people with sickle cell disease approach the healthcare system looking for pain relief only to hear providers quickly judge them as drug seekers — a reality that drives Global Blood Therapeutics (GBT) to … Read more

Potential Policy Changes that Could Upend Prescription Drug Pricing

On November 3, 2021, Congress introduced a working draft of the Build Back Better (BBB) ​​Act. This legislation includes proposals that could drive some of the most material changes in drug pricing in the history of the Medicare Parts B and D programs. The changes are sweeping, with potential for some—such as inflation rebates—to be … Read more